trial
as of 2026-07-01Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
NCTId NCT00641745
at a glance
Phase 3 · Completed
Enrollment 629 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2010-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
629 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-03
Primary completion
2010-07
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Medical Director, MDStudy Director
Sites
73 total
Little Rock, United StatesLittle Rock, United StatesAnaheim, United StatesCerritos, United StatesCosta Mesa, United StatesGarden Grove, United StatesLos Angeles, United StatesOceanside, United StatesOrange, United StatesPasadena, United StatesPico Rivera, United StatesRiverside, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
629
Phase
PHASE3
Primary Completion Date
2010-07
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
indication
investigator
person